Last reviewed · How we verify
Sutetinib Maleate Capsule
Sutetinib Maleate Capsule is a Small molecule drug developed by Teligene US. It is currently in Phase 2 development. Also known as: Sutetinib.
At a glance
| Generic name | Sutetinib Maleate Capsule |
|---|---|
| Also known as | Sutetinib |
| Sponsor | Teligene US |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sutetinib Maleate Capsule CI brief — competitive landscape report
- Sutetinib Maleate Capsule updates RSS · CI watch RSS
- Teligene US portfolio CI
Frequently asked questions about Sutetinib Maleate Capsule
What is Sutetinib Maleate Capsule?
Sutetinib Maleate Capsule is a Small molecule drug developed by Teligene US.
Who makes Sutetinib Maleate Capsule?
Sutetinib Maleate Capsule is developed by Teligene US (see full Teligene US pipeline at /company/teligene-us).
Is Sutetinib Maleate Capsule also known as anything else?
Sutetinib Maleate Capsule is also known as Sutetinib.
What development phase is Sutetinib Maleate Capsule in?
Sutetinib Maleate Capsule is in Phase 2.
Related
- Manufacturer: Teligene US — full pipeline
- Also known as: Sutetinib
- Compare: Sutetinib Maleate Capsule vs similar drugs
- Pricing: Sutetinib Maleate Capsule cost, discount & access